Company Overview: Trovagene

About the Company

Facebook Tweeter Linkedin

We are a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging our proprietary Precision Cancer Monitoring® (PCM) technology and experience in tumor genomics.

Our broad intellectual property and proprietary technology allow us to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting patient response to cancer therapies.

We offer our PCM technology at our CLIA/CAP-accredited laboratory and plan to continue to vertically integrate our PCM technology with the development of precision cancer therapeutics. We believe our ctDNA PCM technology and expertise in liquid biopsy testing provides a unique advantage for the development of precision cancer therapeutics.

PCM-075: Our Lead Product Candidate

Our lead product candidate, PCM-075, was licensed from Nerviano Medical Sciences, S.r.l., a leading European oncology research and discovery organization, and is being developed for the treatment of patients with acute myeloid leukemia (AML).

PCM-075 is an oral and highly-selective polo-like kinase 1 (PLK1) inhibitor and allows us to leverage our PCM technology, and expertise in tumor genomics, to optimize the clinical development process, and uniquely positions us to bring a first-in-class PLK1 inhibitor to the market for the treatment of AML. We plan to leverage our technology and expertise to develop a PCM-075 AML biomarker panel to identify and measure patient response to therapy.

Investor Toolkit

Company News

Email Subscription


Follow this blog

Get every new post delivered right to your inbox.

Email address